WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Kaia Parenti
Patent Agent
Patents and Innovations
San Diego
kparenti@wsgr.com

D212-453-2852

Download vCard
Open PDF

Dr. Kaia Parenti is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes extensive knowledge in organic chemistry, polymer materials, physical chemistry, and nanotechnology. Kaia applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, and biotechnology industries.

Prior to joining the firm, Kaia completed her doctoral degree at Columbia University where her dissertation focused on the design, synthesis, and photophysical characterization of organic semiconductors for multiple exciton generation. While at Columbia, Kaia also served as a fellow in the university’s technology transfer office, Columbia Technology Ventures.

Experience

Dr. Kaia Parenti is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes extensive knowledge in organic chemistry, polymer materials, physical chemistry, and nanotechnology. Kaia applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, and biotechnology industries.

Prior to joining the firm, Kaia completed her doctoral degree at Columbia University where her dissertation focused on the design, synthesis, and photophysical characterization of organic semiconductors for multiple exciton generation. While at Columbia, Kaia also served as a fellow in the university’s technology transfer office, Columbia Technology Ventures.

Education
  • Ph.D., Chemistry, Columbia University, 2022

    National Defense Science and Engineering Graduate Fellow

  • B.S., Biochemistry, University of Michigan, 2017
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Ph.D., Chemistry, Columbia University, 2022

    National Defense Science and Engineering Graduate Fellow

  • B.S., Biochemistry, University of Michigan, 2017
Admissions
  • U.S. Patent and Trademark Office

Select Publications

    • Co-author, “Direct Exciton Harvesting from a Bound Triplet Pair,” Advanced Materials 2203974, 2022
    • Co-author, “Quantifying Exciton Transport in Singlet Fission Diblock Copolymers,” 144(7) Journal of the American Chemical Society 3269-3278, 2022
    • Co-author, “Pentacene-Bridge Interactions in an Axially Chiral Binaphthyl Pentacene Dimer,” 125(33) Journal of Physical Chemistry A 7226-7234, 2021
    • Lead author, “Bridge Resonance Effects in Singlet Fission,” 124(45) Journal of Physical Chemistry A 9392-9399, 2020
    • Co-author, “Understanding the Bound Triplet-Pair State in Singlet Fission,” 5(8) Chem 1988-2005, 2019
    • Co-author, “Microphase Segregation and Selective Chain Scission of Poly(2‐Methyl‐2‐Oxazoline)‐Block‐Polystyrene,” 57(2) Journal of Polymer Science Part A: Polymer Chemistry 1349-1357, 2019
    • Co-author, “Persistent Multiexcitons From Polymers with Pendent Pentacenes,” 141(24) Journal of the American Chemical Society 9564-9569, 2019
    • Co-author, “Hierarchical Patterns with Sub-20 nm Pattern Fidelity via Block Copolymer Self-Assembly and Soft Nanotransfer Printing,” 10(23) Polymer Chemistry 3194-3200, 2019
    • Co-author, “Asymmetric Palladium‐Catalyzed Alkene Carboamination Reactions for the Synthesis of Cyclic Sulfamides,” 22(17) Chemistry – A European Journal 5919-5922, 2016
Insights

Select Publications

    • Co-author, “Direct Exciton Harvesting from a Bound Triplet Pair,” Advanced Materials 2203974, 2022
    • Co-author, “Quantifying Exciton Transport in Singlet Fission Diblock Copolymers,” 144(7) Journal of the American Chemical Society 3269-3278, 2022
    • Co-author, “Pentacene-Bridge Interactions in an Axially Chiral Binaphthyl Pentacene Dimer,” 125(33) Journal of Physical Chemistry A 7226-7234, 2021
    • Lead author, “Bridge Resonance Effects in Singlet Fission,” 124(45) Journal of Physical Chemistry A 9392-9399, 2020
    • Co-author, “Understanding the Bound Triplet-Pair State in Singlet Fission,” 5(8) Chem 1988-2005, 2019
    • Co-author, “Microphase Segregation and Selective Chain Scission of Poly(2‐Methyl‐2‐Oxazoline)‐Block‐Polystyrene,” 57(2) Journal of Polymer Science Part A: Polymer Chemistry 1349-1357, 2019
    • Co-author, “Persistent Multiexcitons From Polymers with Pendent Pentacenes,” 141(24) Journal of the American Chemical Society 9564-9569, 2019
    • Co-author, “Hierarchical Patterns with Sub-20 nm Pattern Fidelity via Block Copolymer Self-Assembly and Soft Nanotransfer Printing,” 10(23) Polymer Chemistry 3194-3200, 2019
    • Co-author, “Asymmetric Palladium‐Catalyzed Alkene Carboamination Reactions for the Synthesis of Cyclic Sulfamides,” 22(17) Chemistry – A European Journal 5919-5922, 2016

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • Drug conjugates
  • Drug conjugates based drug discovery
  • Drug delivery
  • Peptide therapeutics
  • Pharmacodynamics
  • Pharmacokinetics
  • Small molecule synthesis
  • Small molecules

Chemistry and Material Science

  • Chemical synthesis
  • Chemistry
  • Materials chemistry
  • Organic chemistry
  • Organometallics
  • Process chemistry
Technical Fluency

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • Drug conjugates
  • Drug conjugates based drug discovery
  • Drug delivery
  • Peptide therapeutics
  • Pharmacodynamics
  • Pharmacokinetics
  • Small molecule synthesis
  • Small molecules

Chemistry and Material Science

  • Chemical synthesis
  • Chemistry
  • Materials chemistry
  • Organic chemistry
  • Organometallics
  • Process chemistry
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Firm Advises Frazier Life Sciences on Patent Matters Related to AirNexis Therapeutics’ $200 Million Series A Financing
On January 9, 2026, AirNexis Therapeutics, a clinical-stage biotech company developing therapeutics for pulmonary diseases, announced the closing of a $200 million Series A financing round and the in-license of a dual PDE3/4 inhibitor in Phase 2 development for chronic obstructive pulmonary disease (COPD) from Haisco Pharmaceutical Group. The financing was led by founder Frazier Life Sciences, with participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital, and Enavate Sciences, among others.
Learn More
Client Highlights
Wilson Sonsini Advises AXA IM Alts on Patent Matters Related to Imbria Pharmaceuticals’ Upsized Series B Financing
On November 17, 2025, Imbria Pharmaceuticals, a clinical-stage company developing transformational cardiovascular disease therapeutics, announced the participation of AXA IM Alts in an upsized Series B financing. With this investment, AXA IM Alts joins a leading investor syndicate that includes RA Capital, SV Health Investors, Deep Track Capital, AN Ventures, Catalio Capital Management, and Cytokinetics. Wilson Sonsini Goodrich & Rosati advised AXA IM Alts on patent matters related to the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.